116 related articles for article (PubMed ID: 23857029)
1. In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.
Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
Drug Metab Pharmacokinet; 2014; 29(1):52-60. PubMed ID: 23857029
[TBL] [Abstract][Full Text] [Related]
2. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
3. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
4. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
6. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
[TBL] [Abstract][Full Text] [Related]
7. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling of human CYP2D6 and molecular docking of a series of ajmalicine- and quinidine-like inhibitors.
Saraceno M; Coi A; Bianucci AM
Int J Biol Macromol; 2008 May; 42(4):362-71. PubMed ID: 18346782
[TBL] [Abstract][Full Text] [Related]
10. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
11. Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
Fischer A; Don CG; Smieško M
J Chem Inf Model; 2018 Sep; 58(9):1962-1975. PubMed ID: 30126275
[TBL] [Abstract][Full Text] [Related]
12. Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site.
Berka K; Anzenbacherová E; Hendrychová T; Lange R; Mašek V; Anzenbacher P; Otyepka M
J Inorg Biochem; 2012 May; 110():46-50. PubMed ID: 22459173
[TBL] [Abstract][Full Text] [Related]
13. Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.
Olubiyi OO; Olagunju MO; Obisesan AO
Curr Comput Aided Drug Des; 2017; 13(1):39-47. PubMed ID: 27632988
[TBL] [Abstract][Full Text] [Related]
14. Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C.
Kim J; Lim YR; Han S; Han JS; Chun YJ; Yun CH; Lee CH; Kim D
Arch Pharm Res; 2013 Dec; 36(12):1500-6. PubMed ID: 23897164
[TBL] [Abstract][Full Text] [Related]
15. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
16. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap).
Mo SL; Liu WF; Chen Y; Luo HB; Sun LB; Chen XW; Zhou ZW; Sneed KB; Li CG; Du YM; Liang J; Zhou SF
Comb Chem High Throughput Screen; 2012 Jan; 15(1):36-80. PubMed ID: 21846324
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels.
de Waal PW; Sunden KF; Furge LL
PLoS One; 2014; 9(10):e108607. PubMed ID: 25286176
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution.
Fischer A; Smieško M
Sci Rep; 2019 Nov; 9(1):16411. PubMed ID: 31712722
[TBL] [Abstract][Full Text] [Related]
20. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
